Pegylated interferon, but not conventional interferon therapy induced severe skin lesions

Annals of Hepatology

Volumn 11, Issue 4, 2012, Pages 570-571

  Li, Zhengxiao ^a   Ji, Fanpu ^a   Zheng, Yan ^a   An, Jingang ^a   Peng, Zhenhui ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; MIZOLASTINE; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DISEASE SEVERITY; ECZEMA; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE SKIN LESION; LABORATORY TEST; LETTER; LICHENOID ERUPTION; LIVER BIOPSY; LIVER FIBROSIS; MALAISE; PAPULAR RASH; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; SKIN DEFECT; TREATMENT DURATION; VIRUS LOAD; DRUG COMBINATION; DRUG EFFECT; DRUG ERUPTION; HOSPITALIZATION; INJECTION; MIDDLE AGED; PATHOLOGY; SKIN; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTIVIRAL AGENTS; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; INJECTIONS; INTERFERON-ALPHA; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME;

EID: 84862003420     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31475-9     Document Type: Letter

References (6)

1. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-8.
2. Edwards IR, Aronson JK. Adverse drugs reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9.
3. Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol 2002; 147: 1142-6.
4. Lübbe J, Kerl K, Negro F, Saurat JH. Clinical and immunological features of hepatitis C treatment associated dermatitis in 36 prospective cases. Br J Dermatol 2005; 153: 10888-90.
5. Hashimoto Y, Kanto H, Itoh M. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J Dermatol 2007; 34: 577-82.
6. Veldt BJ, Schalm SW, Janssen HL. Severe allergic eczema due to pegylated alfa interferon may abate after switching to daily conventional alfa interferon. J Clin Gastroenterol 2007; 41: 432.